Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

Abstract Number: 2461 • 2017 ACR/ARHP Annual Meeting
Rituximab Is Effective in the Treatment of Rheumatoid Arthritis Irrespective of Body Mass Index; Up to 48 Weeks Results from Phase 3 Study
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Sang-Joon Lee⁵, Yun Ju Bae⁵, Chan Park⁵ and Noo Ri Han⁵, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ³Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁵CELLTRION, Inc., Incheon, Korea, Republic of (South)
Background/Purpose: High body mass index (BMI) is known to be associated with inadequate clinical response to anti-TNF agents in RA patients.1 However, there are limited…
Abstract Number: 2486 • 2017 ACR/ARHP Annual Meeting
Rituximab Is an Attractive Proposition to Treat Difficult Active RA in Indian (Asia) Patients: Initial Results of a Non Commercial Initiative Using an Initial Regimen of Two 500 Mg Infusions (fortnightly) and a Third 500 Mg Infusion at 6 Weeks in Case of Inadequate Response(ACR 50)
Arvind Chopra¹, KIRAN ADAM², NACHIKET KULKARNI³, Anuradha Venugopalan⁴, Toktam Kainifard⁵ and Manjit Saluja⁶, ¹Center for Rheumatic Diseases, Pune, India, Pune, India, ²Rheumatology physician, PUNE, India, ³MD, DNB, PUNE, India, ⁴Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India, ⁵Rheumatology, Consultant research and Dietitian, Pune, India, ⁶Rheumatology, Co-ordinator Research, Pune, India
Background/Purpose: Considering the huge burden of RA in India, the use of biologic DMARDs is miniscule. The major deterrents are cost, poor awareness and few…
Abstract Number: 2000 • 2016 ACR/ARHP Annual Meeting
Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Alain Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, RENE MARC FLIPO⁷, Olivier Vittecoq⁸, Thierry Schaeverbeke⁹, Isabelle Pane¹⁰, Jean Sibilia¹¹, Xavier Mariette¹² and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hotel Dieu, PARIS, France, ³Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁹Rheumatology, CHU Bordeaux, Bordeaux, France, ¹⁰Epidemiology, Hotel Dieu, Paris, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of…
Abstract Number: 2117 • 2016 ACR/ARHP Annual Meeting
B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab
Geraldine Cambridge¹, Rita A. Moura², Venkat Reddy³ and Maria J. Leandro¹, ¹Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ²Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Repeat treatment with rituximab (RTX) predisposes some patients with rheumatoid arthritis (RA) to develop low levels of serum immunoglobulins (Igs). Understanding B cell function…
Abstract Number: 3089 • 2016 ACR/ARHP Annual Meeting
Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis
Duncan Porter¹, C. S. Goodyear², J. S. Nijjar¹, Martina Messow³, Stefan Siebert¹, Manikhandan Mudaliar⁴ and Iain B. McInnes⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom, ⁴Glasgow Polyomics Facility, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain
Background/Purpose: The ORBIT study demonstrated that rituximab is non-inferior to a TNFi-first strategy in biologic naive, sero-positive patients with active RA over 12 months (Lancet…
Abstract Number: 366 • 2016 ACR/ARHP Annual Meeting
Peripheral Osteoclastogensis Is Coming Back Along with Inflammation Twelve Months after Rituximab Therapy
Mie Jin Lim¹, Won Park², Seong-Ryul Kwon³ and Kyong-Hee Jung⁴, ¹Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, ²Medicine/Rheumatology, IN-HA University Hospital, Choong-Gu Incheon, Korea, Republic of, ³Center for Rheumatism, Inha University Hospital, Incheon, South Korea, ⁴Hospital for Rheumatic Disease, Hanyang Univ Medical Center, Seoul, South Korea
Background/Purpose: We investigated change of bone turnover markers in peripheral blood before, 6 and 12 months after rituximab therapy in seropositive RA patients. Methods: Ten…
Abstract Number: 1580 • 2016 ACR/ARHP Annual Meeting
Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the US Corrona Registry
Leslie R Harrold¹, Ani John², Jennie Best², Steve Zlotnick², Chitra Karki³, YouFu Li⁴, Jeffrey D. Greenberg⁵ and Joel Kremer⁶, ¹UMass Medical School, Worcester, MA, ²Genentech, Inc., South San Francisco, CA, ³Corrona, LLC, Southborough, MA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵New York University School of Medicine, New York, NY, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience diminished quality of life and increased disability. Patient-reported outcomes (PROs) are important measures of response to therapy in…
Abstract Number: 1634 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Chang-Hee Suh¹, Alfredo Berrocal Kasay², Elias Chalouhi El-Khouri³, Pedro Miranda⁴, Ljubinka Bozic Majstorovic⁵, Slawomir Jeka⁶, Pawel Hrycaj⁷, Dmytro Rekalov⁸, Piotr Wiland⁹, Andreas Krause¹⁰, Istvan Szombati¹¹, Anna Mihailova¹², Ihor Hospodarskyy¹³, Mariusz Piotrowski¹⁴, Seong-Ryul Kwon¹⁵, Eun-Young Lee¹⁶, Dae-Hyun Yoo¹⁷, Won Park¹⁸, Seung-Cheol Shim¹⁹, Sang-Joon Lee²⁰ and Taek S. Kwon²⁰, ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, The Republic of, ²ABK Reuma SRL – Medicentro Biociencias, Lima, Peru, ³Clinica Internacional, Lima, Peru, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Clinical Centre Banja Luka, Bonja Luka, Bosnia and Herzegovina, ⁶Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital, CM UMK, Bydgoszcz, Poland, ⁷Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, ⁸Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, ⁹Uniwersytecki Szpital Kliniczny im. Jana Mikulicza- Radeckigo, Wroclaw, Poland, ¹⁰Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ¹¹QUALICLINIC Kft., Budapest, Hungary, ¹²Orto clinic Ltd., Riga, Latvia, ¹³Ternopil State Medical University, Ternopil, Ukraine, ¹⁴Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland, Lublin, Poland, ¹⁵Internal Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ¹⁶Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ¹⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁸Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ¹⁹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ²⁰CELLTRION, Inc., Incheon, South Korea
Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Result from Phase 3…
Abstract Number: 1635 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Dae-Hyun Yoo¹, Ljubinka Bozic Majstorovic², Alfredo Berrocal Kasay³, Elias Chalouhi El-Khouri⁴, Fedra Irazoque-Palazuelos⁵, Francisco Cons Molina⁶, Pedro Miranda⁷, Pavel Shesternya⁸, Francisco G. Medina-Rodriguez⁹, Piotr Wiland¹⁰, Slawomir Jeka¹¹, Olena Garmish¹², Pawel Hrycaj¹³, Dmytro Rekalov¹⁴, Natalia Fomina¹⁵, Devy Zisman¹⁶, Yong-Beom Park¹⁷, Young Mo Kang¹⁸, Chang-Hee Suh¹⁹, Seung Cheol Shim²⁰, Sang Joon Lee²¹, Sung Young Lee²² and Won Park²³, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Clinical Centre Banja Luka, Bonja Luka, Bosnia and Herzegovina, ³ABK Reuma SRL – Medicentro Biociencias, Lima, Peru, ⁴Clinica Internacional, Lima, Peru, ⁵Centro de Invstigacion y Tratamiento Reumatologico S.C, Mexico City, Mexico, ⁶Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁷Centro De Estudios Reumatológicos, Santiago, Chile, ⁸State Budgetary Educational Institution of High Professional Education "Krasnoyarsk state medical university n.a. professor V.F.Voino-Yasenetsky" Ministry of Health of Russian Federation, Krasnoyarsk, Russian Federation, ⁹Biologics Especializados SA, Mexico City, Mexico, ¹⁰Uniwersytecki Szpital Kliniczny im. Jana Mikulicza- Radeckigo, Wroclaw, Poland, ¹¹Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital, CM UMK, Bydgoszcz, Poland, ¹²Institute of Cardiology named by M.D. Strazhesko NAMS of Ukraine, Kyiv, Ukraine, ¹³Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, ¹⁴Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, ¹⁵Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation, ¹⁶The Lady Davis, Haifa, Israel, ¹⁷Dept of Internal Medicine, Severance Hospital, Seoul, Korea, The Republic of, ¹⁸Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of, ¹⁹Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, The Republic of, ²⁰Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ²¹CELLTRION, Inc., Incheon, South Korea, ²²Clinical Planning Department, CELLTRION, Inc., Incheon, South Korea, ²³Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea
Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Result from Phase 3 Randomized Controlled Trial over 24…
Abstract Number: 494 • 2015 ACR/ARHP Annual Meeting
High C-Reactive Protein at Baseline Is Associated with Long-Term Treatment Persistence in Patients with Rheumatoid Arthritis Treated with Rituximab
Maria Joao Gonçalves^1,2, Geraldine Cambridge³ and Maria J. Leandro³, ¹Rheumatology Department, Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom, ²Rheumatology Department, Lisbon Academic Medical Centre, Lisbon, Portugal, ³Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom
Background/Purpose: B cell depletion with rituximab (RTX) is an established treatment for RA. It was first introduced at UCL in 1998 and at this centre…
Abstract Number: 565 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Sustained Response in Patients with Rheumatoid Arthritis Who Received Rituximab within the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed¹, Chitra Karki², Robert Magner¹, Joel M. Kremer⁴, Ashwini Shewede³ and Jeffrey Greenberg^2,5, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY, ⁵NYU School of Medicine, New York, NY
Background/Purpose: The goal of treatment for patients with rheumatoid arthritis (RA) is to achieve and maintain low disease activity (LDA) or remission. Little information is…
Abstract Number: 602 • 2015 ACR/ARHP Annual Meeting
Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study
Padmanabha Shenoy¹ and Manish Bavaliya², ¹Dept. of rheumatology and clinical immunology, Amrita Institute of medical science and research institute, Kochi, India, ²Department of rheumatology and clinical immunology, Amrita institute of medical sciences and research institute, Kochi, India
Background/Purpose: Rituximab is an anti-CD20 antibody that represents a therapeutic alternative for the patients with rheumatoid arthritis. It has been proven that rituximab at a…
Abstract Number: 603 • 2015 ACR/ARHP Annual Meeting
Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset
Elizabeth M.A. Hensor^1,2, Edward M. Vital^1,2 and Paul Emery^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Seronegative RA patients have inferior clinical response to rituximab [1]. However, there is significant heterogeneity in this group of patients for baseline clinical features…
Abstract Number: 751 • 2015 ACR/ARHP Annual Meeting
Rituximab Induced Serum Sickness: A Systematic Review
Paras Karmacharya¹, Dilli Poudel¹, Ranjan Pathak¹, Anthony Donato², Sushil Ghimire¹, Smith Giri³, Madan Aryal¹ and Clifton O. Bingham III⁴, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, WEST READING, PA, ³Internal medicine, University of Tennessee Health Science Center, Memphis, TN, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Rituximab (anti-CD20 monoclonal antibody) has been frequently used to treat various autoimmune diseases in which B-cells are participants, and for hematological malignancies in which…
Abstract Number: 1040 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Long Term Rituximab Use in Rheumatoid Arthritis – Results from the British Society of Rheumatology Biologics Register
Alexander G.S. Oldroyd¹, Deborah P.M. Symmons¹, Lianne Kearsley-Fleet¹, Kath Watson¹, Mark Lunt², Jamie Sergeant¹, Kimme L. Hyrich¹ and on behalf of the BSRBR-RA, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Analysis of long term continuation of biologics in rheumatoid arthritis (RA) is considered a valid surrogate for treatment effectiveness and safety. Only a small…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].